Reactive arthritis · Clinical perspective · Chapter 03
The First Visit: Establishing a Working Diagnosis
Resolve the dangerous alternatives, establish the inflammatory pattern and leave a testable explanation for the next visit.
On this page
- Triage before attribution
- Interpret the aspirate as evidence, not a verdict
- Build a two-event timeline
- Choose the competing diagnoses deliberately
- Order only what answers a current question
- Leave with a plan that can be checked
- Separate three diagnostic claims
- The STI branch: do not merge reactive and disseminated infection
- Make the first follow-up capable of changing the plan
Triage before attribution
A newly hot, swollen joint is a clinical problem before it is a diagnostic label. Assess systemic illness, hemodynamic stability, fever, skin breaks, recent procedures, immunosuppression and the speed of deterioration. Septic arthritis can occur without fever and with unremarkable early blood tests.
When septic arthritis is suspected, arrange prompt aspiration and specialist management. Send synovial fluid for microbiology, cell count with differential and crystals as feasible; prioritize microbiological identification if sample volume is limited. Obtain blood cultures when bacteremia or sepsis is suspected. In a stable patient, sampling generally precedes antibiotics; sepsis demands urgent treatment without a harmful delay. [1]
Interpret the aspirate as evidence, not a verdict
A high synovial leukocyte count raises concern but does not reliably separate bacterial arthritis from intense sterile inflammation. A low count does not absolutely exclude infection, particularly in an immunosuppressed patient. A negative Gram stain is not a rule-out test. Crystals establish crystal deposition in the sample; they do not exclude simultaneous infection.
The clinical context determines whether a negative culture is reassuring. Prior antibiotics, an inadequate sample or a difficult organism may leave residual uncertainty. Do not inject glucocorticoid into a joint while infection remains a serious possibility. Culture follow-up needs a named clinician and a plan for contacting the patient.
Build a two-event timeline
Document the onset, duration and resolution of gastrointestinal or genitourinary symptoms, the date of any microbiological sample, the antimicrobial agent and dates, and the onset of joint, enthesis, eye or skin symptoms. Look for earlier similar episodes. A pattern over several weeks is more informative than the phrase “after an infection.”
Ask whether objective infection evidence exists, whether symptoms are continuing, and whether a current infection requires treatment. A late negative test may miss an antecedent infection; it does not justify inventing one. Conversely, a currently positive test supports infection at the sampled site but does not alone establish why the knee is swollen. [2]
Choose the competing diagnoses deliberately
| Alternative | Finding that changes the next step |
|---|---|
| Septic arthritis, including gonococcal disease | Urgent joint assessment; appropriate synovial, blood and exposure-site microbiology |
| Gout or CPP crystal arthritis | Aspiration and crystal analysis; retain infection in the differential |
| Psoriatic arthritis | Skin and nail examination, family history, previous dactylitis or enthesitis |
| IBD-associated SpA | Persistent diarrhea, bleeding, weight loss or established bowel disease |
| Lyme arthritis | Compatible geography and exposure; use the recommended serological pathway |
| Rheumatoid or viral arthritis | Distribution, duration, systemic clues and targeted testing |
| Mechanical injury or tendon disorder | Localized loading-related symptoms and a concordant examination |
A swollen knee in a Lyme-endemic region deserves a different diagnostic pathway from an indiscriminate Lyme screen in a low-probability setting. Antibiotic-responsive Lyme arthritis should not be relabeled as ordinary ReA. [3]
Order only what answers a current question
Baseline inflammatory markers can help describe and follow the episode. Blood count, renal and liver tests may be needed both for differential diagnosis and before treatment. Order chlamydial and gonococcal NAAT according to sexual history and local STI guidance; discuss HIV and syphilis testing where indicated. Stool testing is most useful when there is an ongoing enteric syndrome or a specific public-health or diagnostic reason. [4]
HLA-B27 may assist selected SpA evaluations, but it is not an emergency test or a treatment threshold. Rheumatoid factor, anti-CCP, ANA and broad infection serologies should follow a specific alternative hypothesis. A longer panel is not the same as a more defensible assessment.
Leave with a plan that can be checked
Explain what is likely, what has been excluded and what still needs confirmation. Agree on an anti-inflammatory strategy once infection risk has been addressed; give explicit instructions for worsening joint symptoms, systemic illness or new eye symptoms. Ensure that pending cultures and STI results will be reviewed.
Arrange follow-up according to severity rather than a fixed diagnostic waiting period. At review, ask whether objective inflammation and function have improved, whether medication was tolerated, and whether new findings alter the diagnosis. A working diagnosis is useful when it leads to these observable decisions.
Separate three diagnostic claims
A useful first-visit formulation separates the inflammatory syndrome, evidence of the antecedent or current infection, and the proposed causal link. These are not interchangeable. An observed knee effusion and enthesitis may establish an inflammatory phenotype; a positive genital NAAT establishes infection at the sampled site; the timing and the competing explanations determine how persuasive the ReA attribution is.
Record the source and timing of each item. A patient-reported diarrheal episode, a contemporaneous positive stool test and a remote antibody result carry different information. “Probable reactive arthritis after an unconfirmed enteric illness” is more transparent than silently treating an assumed organism as established. This distinction also prevents an uncertain trigger from obscuring a well-documented need to treat inflammation.
The practical hierarchy is: identify what requires action today, state what the evidence supports, and name what could overturn the working explanation. This is a clinical reasoning framework, not a validated diagnostic score.
The STI branch: do not merge reactive and disseminated infection
Disseminated gonococcal infection may present with acral skin lesions, asymmetric polyarthralgia, tenosynovitis or oligoarticular septic arthritis; genital symptoms may be absent. A compatible exposure history plus this pattern should open an infectious-disease pathway, not simply reinforce a diagnosis of reactive arthritis.
CDC guidance recommends sampling exposed mucosal sites and disseminated sites as appropriate, with culture and antimicrobial susceptibility assessment where indicated. Initial hospitalization and infectious-disease consultation are recommended for DGI, particularly with diagnostic uncertainty, purulent effusions or other complications. The diagnostic and treatment pathway differs from uncomplicated genital infection. [6]
Separately, a chlamydial NAAT obtained less than four weeks after treatment can remain positive because nonviable organisms are detected. Distinguish a test of cure from later testing for reinfection, and interpret the result with adherence, symptoms, pregnancy status and re-exposure in mind. Repeating an early test until it becomes negative is not a reliable way to determine whether joint inflammation is still infection-driven. [2]
Make the first follow-up capable of changing the plan
Document a small set of findings that can be compared: which joints are swollen, which entheses are symptomatic, the major functional limitation, the current anti-inflammatory exposure and any relevant baseline inflammatory marker. A statement such as “pain better” is hard to interpret if prednisone was increased and the effusion remains.
At review, distinguish three outcomes:
- Improvement with falling treatment burden: the initial strategy may be working; continue reassessment and rehabilitation.
- Ongoing objective inflammation or recurrent effusion: review sampling results, adequacy and tolerability of treatment, and the need for local or systemic escalation.
- Persistent symptoms with a changed pattern: reopen the differential instead of automatically repeating the same prescription.
There is no single universally validated first-visit ReA score that resolves these decisions. The examination, relevant testing and the evolving phenotype remain central. Normal CRP or a negative HLA-B27 result must not independently close a SpA assessment. [7]
Use the investigation selector for question-based testing and the longitudinal reassessment chapter for the next visit.
Sources and further reading
- Ravn C et al. Guideline for management of septic arthritis in native joints (SANJO). J Bone Jt Infect. 2023;8:29–37.
- CDC. STI Treatment Guidelines: Chlamydial Infections.
- AAN/ACR/IDSA. Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. 2020.
- IDSA. Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. 2017.
- Carlin E, Marzo-Ortega H, Flew S. British Association for Sexual Health and HIV national guideline on the management of sexually acquired reactive arthritis 2021.
- CDC. STI Treatment Guidelines: Gonococcal Infections Among Adolescents and Adults; Disseminated Gonococcal Infection.
- NICE NG65. Spondyloarthritis in over 16s: diagnosis and management. Recommendations, including reactive arthritis and long-term antibiotics.
Educational information. Your treatment plan depends on your examination, test results and medical history.